Pfizer Vaccine Blood Clots
Pfizer Vaccine Blood Clots. Israeli study links Pfizer vaccine to deadly blood disease that causes blood clots
Pfizer Vaccine Blood Clots
Israeli researchers have found that Pfizer’s COVID-19 vaccine is linked to a deadly blood disease that causes clots to form around the body.
Researchers from the Institute of Hematology at Shamir Medical Center in central Israel announced that the Pfizer-BioNTech vaccine can cause thrombotic thrombocytopenic purpura (TTP), an autoimmune disease that affects the blood.
TTP most commonly attacks small blood vessels around the body by causing blood clots (thrombi) to form. These clots can cause serious health problems if they fully block the vessels and restrict blood flow to the body’s organs such as the kidneys, heart and brain. (Related: Pfizer vaccine linked to heart inflammation in young men, Israeli experts conclude.)
The researchers from Shamir Medical were alerted to the problem after seeing a surge in TTP cases. Before the coronavirus pandemic, medical institutions in Israel would only detect a handful of cases per year. Now, health experts are seeing many cases every month.
The team that conducted the research said they found a “chronological connection” between the vaccination of Israelis with the Pfizer vaccine and the onset of TTP symptoms. They stressed that symptoms can arise in both newly-vaccinated individuals and in people whose TTP symptoms flared up after a long period of remission.
Despite the findings of the study, the research team behind it still supports vaccinations against COVID-19.
A spokesperson for Shamir Medical stressed that the study should not deter people from getting vaccinated. He encouraged anybody who has not yet been vaccinated to do so immediately.
Dr. Maya Koren-Michowitz, lead researcher and head of the Hematology and Translational Hemato-Oncology Laboratory at Shamir Medical, recommended that people with TTP get a medical clearance from their doctors before they get vaccinated. And if they do proceed with getting the coronavirus vaccine, she has asked these people to go to regular clinical evaluations to make sure they do not get blood clots.
The researchers have also called on vaccinated and “healthy people” to be vigilant and seek medical help immediately if TTP symptoms appear.
“Physicians and patients need to be alert to the clinical symptoms [of TTP]: weakness, fatigue, neurological disorders, hemorrhage and chest pain,” wrote the research team in a press release.
They pointed out that early diagnosis, combined with modern medical treatments, has increased the survival rate of TTP patients from 10 percent in the past to around 80 percent today.
The Israeli Ministry of Health is in the process of evaluating the research. Until the evaluation is complete, the ministry has asked the researchers from Shamir Medical to not consent to any further interviews.
Pfizer CEO Not Take Pfizer Covid-19 Vaccine ?
Something Fishy’: Pfizer CEO Not Getting His Own Company’s Covid-19 Vaccine Raises Questions
Pfizer’s CEO Albert Bourla has not received his own company’s vaccine yet.
‘Something Fishy’: Pfizer CEO Not Getting His Own Company’s Covid-19 Vaccine Raises Questions
The Covid-19 vaccine developed by Pfizer and BioNTech became the first to be approved for use when the United Kingdom gave it the green light. The UK’s decision came as a welcome move as it signalled the end of the ongoing coronavirus pandemic.
After UK, the United States also approved the vaccine for emergency use in the country. On Monday, the United States kicked off a mass vaccination drive hoping to turn the tide on the world’s biggest coronavirus outbreak, as the country’s death toll neared a staggering 300,000. Canada, too, administered its first doses of a Covid-19 vaccine, becoming one of the first countries to do so in the effort to beat the pandemic.
Singapore too approved the Pfizer-BioNTech coronavirus vaccine, and expects to receive the first shipments of the shots by the end of December.
However, Pfizer’s CEO Albert Bourla has not received his own company’s vaccine yet. According to a report by CNN, Bourla said that neither he nor other company executives will be cutting the line to get their hands on the jabs first. Bourla was speaking to CNN’s Sanjay Gupta when he explained why he wouldn’t be one of the first people in the world to get vaccinated against Covid-19.
There are limited doses available as vaccination begins in the US and the health authorities are prioritising the most vulnerable groups and healthcare workers fighting the pandemic from the frontline for the vaccine. Hence, Bourla feels that it would be unfair if he were to cut the queue and get the vaccine first.
Bourla also asserted that he was not a frontline worker; he said that he is 59 years old and in good health — hence, it would not be appropriate for him to get the vaccine first.
Pfizer Covid19 Vaccine Cause Eye Inflammation
Pfizer Covid-19 vaccine linked to cases of RARE EYE INFLAMMATION (Jerusalem Post report)
The Pfizer jab has been linked to UVEITIS – a rare form of eye inflammation, according to a study by Israel’s Tel Aviv Sourasky Medical Center.
Researchers found 21 people developed anterior uveitis and 2 developed Multiple Evanescent White Dot Syndrome within a fortnight of their first shot or within a month of their second Pfizer jab – 3 of the 21 cases were classed as severe.
Scientists stressed that developing uveitis from Covid vaccination is “quite rare” and that the eye inflammation has been associated with other vaccines.
Subscribe to RT t.me/rtintl
Pfizer Vaccine Reduce Virus Transmission
LONDON (Reuters) – A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.
Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.
“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.
After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.
This compared with 0.37% of tests from staff less than 12 days post-vaccination – when the vaccine’s protective effect is not yet fully established – and 0.20% of tests from staff at 12 days or more post-vaccination.
The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.
This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.
The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.
Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.
“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”
Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.
Pfizer Vaccine 45.79 Million Doses For Malaysian
45.79 million doses of Pfizer-BioNTech vaccine for those yet to be vaccinated
KUALA LUMPUR: The unvaccinated population will receive the Pfizer-BioNTech vaccine as the country has made orders of up to 45.79 million doses.
Health Minister Datuk Seri Dr Adham Baba said there was more supply of the Pfizer-BioNTech vaccine compared to Sinovac, at 16 million.
“Half of the Sinovac vaccines have been dispensed and the supplies now are sufficient to cater to the inoculation of the second dose. It is not just in Kelantan where the Pfizer-BionTech vaccines will be used, but also other states as well,” he said in a special press conference today.
Dr Adham was responding to a statement made by Kelantan health director Datuk Dr Zaini Hussin who reportedly said that all the vaccination centres (PPVs) in the state would switch to Pfizer-BioNTech from Sinovac from next month.
Health director-general Tan Sri Dr Noor Hisham Abdullah said the Pfizer-BioNTech vaccines can immunise 22.2 million people.
“It is now our primary vaccine and its use will be heightened at the PPVs nationwide,” he said.
Dr Noor Hisham added the Drug Control Authority will convene tomorrow to consider the Sinopharm vaccine which had been approved by the World Health Organisation.
“The company had just sent the dossier to the National Pharmaceutical Regulatory Agency. In less than a month, we have evaluated and will decide on its approval tomorrow,” he said.